Literature DB >> 26634250

Comment on: "Regorafenib: Start Low and Go Slow".

Christelle de la Fouchardière1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26634250     DOI： 10.1007/s11523-015-0407-4

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  11 in total

1.  Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.

Authors:  Axel Grothey
Journal:  Clin Adv Hematol Oncol       Date:  2015-08

2.  A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.

Authors:  Klaus Mross; Annette Frost; Simone Steinbild; Susanne Hedbom; Martin Büchert; Ulrike Fasol; Clemens Unger; Jörn Krätzschmar; Roland Heinig; Oliver Boix; Olaf Christensen
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

3.  Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Authors:  Josep Tabernero; Heinz-Josef Lenz; Salvatore Siena; Alberto Sobrero; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Takayuki Yoshino; Richard M Goldberg; Daniel J Sargent; Andrea Wagner; Dirk Laurent; Michael Teufel; Michael Jeffers; Axel Grothey; Eric Van Cutsem
Journal:  Lancet Oncol       Date:  2015-07-13       Impact factor: 41.316

4.  Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jin Li; Shukui Qin; Ruihua Xu; Thomas C C Yau; Brigette Ma; Hongming Pan; Jianming Xu; Yuxian Bai; Yihebali Chi; Liwei Wang; Kun-Huei Yeh; Feng Bi; Ying Cheng; Anh Tuan Le; Jen-Kou Lin; Tianshu Liu; Dong Ma; Christian Kappeler; Joachim Kalmus; Tae Won Kim
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

5.  Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.

Authors:  Daniel A Goldstein; Bilal B Ahmad; Qiushi Chen; Turgay Ayer; David H Howard; Joseph Lipscomb; Bassel F El-Rayes; Christopher R Flowers
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

6.  Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.

Authors:  Axel Grothey; Suzanne George; Eric van Cutsem; Jean-Yves Blay; Alberto Sobrero; George D Demetri
Journal:  Oncologist       Date:  2014-05-12

7.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

8.  Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib.

Authors:  Andrea Li Ann Wong; Joline Si Jing Lim; Arvind Sinha; Anil Gopinathan; Robert Lim; Chee-Seng Tan; Thomas Soh; Sudhakar Venkatesh; Christina Titin; Nur Sabrina Sapari; Soo-Chin Lee; Wei-Peng Yong; David Shao Ping Tan; Brendan Pang; Ting-Ting Wang; Ying-Kiat Zee; Richie Soong; Zuzana Trnkova; Chetan Lathia; Jean-Paul Thiery; Scott Wilhelm; Michael Jeffers; Boon-Cher Goh
Journal:  J Transl Med       Date:  2015-02-12       Impact factor: 5.531

9.  The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.

Authors:  Xiaojun Jiang; Daniel Pissaloux; Christelle De La Fouchardiere; Françoise Desseigne; Qing Wang; Valery Attignon; Marie-Eve Fondrevelle; Arnaud De La Fouchardiere; Maurice Perol; Philippe Cassier; Christelle Seigne; David Perol; Isabelle Ray-Coquard; Pierre Meeus; Jerome Fayette; Aude Flechon; Axel Le Cesne; Nicolas Penel; Olivier Tredan; Jean-Yves Blay
Journal:  Oncotarget       Date:  2015-09-22

10.  Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.

Authors:  D Strumberg; M E Scheulen; B Schultheis; H Richly; A Frost; M Büchert; O Christensen; M Jeffers; R Heinig; O Boix; K Mross
Journal:  Br J Cancer       Date:  2012-05-08       Impact factor: 7.640
View more
  1 in total

1.  Author's Reply to Christelle de la Fouchardière: "Regorafenib: Start Low and Go Slow".

Authors:  Samer Tabchi; Marwan Ghosn
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.